Clinical Read2026-06-03

Darlifarnib (KO-2806) and adagrasib in combination with cabozantinib - (FIT-001)

Bristol-Myers Squibb CompanyBMY
Indication
Clear cell renal cell carcinoma (ccRCC)
Stage
phase1
Event
Phase 1a